Telogen Effluvium and Trichodynia in Different Severity Groups of Post COVID-19 Patients

Arjel A, Pokhrel K

ABSTRACT

Introduction: Telogen Effluvium is one of the most common form of diffuse non scarring hair loss, usually occurring three months after a stressful event causing hair shedding. Trichodynia is an imminent and frequent warning sign of Telogen Effluvium. Increasing cases of Telogen Effluvium during COVID-19 era has been found and it should be an alarming sign for a dermatologist and patients who have been infected by COVID-19 in the past. Aims: To study Telogen Effluvium in post COVID-19 patients, onset of Telogen Effluvium and occurrence of Trichodynia in different severity groups of COVID-19. Methods: This casual-comparative study was conducted from January 2021 to December 2021 in total of 52 Telogen Effluvium patients with confirmed recent COVID-19 disease visiting in outpatient department of Dermatology in Nepalgunj Medical College Teaching Hospital. Patient's with physiological, psychosocial and other chronic illness known to trigger Telogen Effluvium were excluded. Hair pull test was done for diagnosing Telogen Effluvium. Results: The mean age of the study population was 31.0577±11.78 years. There was a female preponderance with 39 (75%). The mean onset of hair loss after COVID-19 infection was 10.05 weeks and was significantly earlier among the higher severity groups. Among the patients with Telogen Effluvium, 16 (30.80%) presented with trichodynia. Kruskal- Wallis test showed that with increase in severity of COVID-19, there was early onset of Telogen Effluvium associated hair loss and increase occurrence of trichodynia with p value of 0.000 for both variables. Conclusion: Telogen Effluvium is common in post COVID patients. Post-COVID Telogen Effluvium is more common in females. The onset of Telogen Effluvium is earlier and is more associated with trichodynia with the increase in severity of COVID-19 during their illness.

Keywords: COVID-19, Hair loss, Telogen Effluvium

Authors:
1. Dr. Abhishek Arjel
2. Dr. Kumar Pokhrel
Department of Dermatology, Nepalgunj Medical College and Teaching Hospital, Nepalgunj, Banke

Address for Correspondence:
Dr. Abhishek Arjel
Department of Dermatology
Nepalgunj Medical College and Teaching Hospital
Nepalgunj, Banke
E mail: drabhishekarjel@gmail.com

INTRODUCTION

Corona Virus Disease-19 (COVID-19) is a rapidly spreading pandemic disease caused by “severe acute respiratory syndrome coronavirus 2” (SARS-CoV-2).\(^1\) The clinical presentation of COVID-19 varies from an asymptomatic infection to a life threatening, multi-organ disease.\(^2\) Besides the respiratory system, skin is one of the common organs that can be affected.\(^3\) The ongoing efforts within dermatology community has documented various cutaneous, hair, nail and mucosal manifestations of COVID-19.\(^2,3,4\)

Telogen Effluvium (TE) is a self-limiting non-scarring alopecia characterized by diffuse hair shedding that occurs after stressful illness and resolves within six months of onset.\(^5\) TE has recently been reported as a post-infectious manifestation of the novel coronavirus SARS-CoV-2, occurring after few months of infection.\(^6\) TE is a delayed consequence of a shift in the hair cycle phase away from anagen where termination of anagen results in the onset of catagen and subsequently telogen.\(^6\) TE in COVID-19 is believed to be provoked by pro-inflammatory cytokines, impaired anti-coagulation and severe psychosocial stress.\(^5\) Trichodynia corresponds to a complex symptom that includes pain, pruritus and/or a burning sensation, most commonly associated with hair loss. It is generally considered as a sign of severity and in some cases it may be a warning symptom of imminent hair shedding which may occur after the trichodynia onset.\(^1\) A careful history and physical examination is sufficient for diagnosis of TE and identification of its causative agent. Prompt diagnosis and management of disease may lead to better health outcomes.\(^7\) As there are very few studies regarding TE in post-COVID patients, we intended to study TE in post-COVID patient and compare its onset and associated symptoms with the severity of COVID-19 disease.

METHODS

This casual-comparative study was conducted from January 2021 to December 2021 in outpatient department of Dermatology in Nepalgunj Medical College Teaching Hospital, after taking ethical clearance from Institutional Review Committee (IRC). Out of 191 cases of Alopecia presenting in OPD during this period, 52 cases who were diagnosed as TE with confirmed recent COVID-19 disease and not falling
under our exclusion criteria were taken as sample size. Patient demographics, COVID-19 infection diagnosis by Polymerase Chain Reaction (PCR), symptoms, severity and duration of COVID-19 were recorded. Duration and onset of hair loss in TE and its associated scalp symptom Trichodynia were also recorded.

The diagnosis of TE was dependent on history and physical examination and confirmed by a hair pull test. Hair pull test was done by grasping 50 to 60 hair between thumb, index, and middle fingers in frontal, occipital, and both temporal regions of the scalp and the test was considered positive if more than 10% of pulled hair away from scalp were in telogen phase and hair with white clubbed bulb.

**Inclusion criteria:** Registry of patients with laboratory confirmed SARS-CoV-2 infection who developed Acute TE with no previous history of hair loss and actively sought medical care at the Dermatology Department were included.

**Exclusion criteria:** All the patients with alopecia visiting our OPD who were COVID-19 negative or haven’t done PCR test, patients with thyroid disorders, pregnancy, iron deficiency anemia, chemotherapy, central nervous system disorders and other chronic diseases requiring drugs like beta-blockers, ACE inhibitors, anti-coagulants etc. were also excluded. Thyroid function test, complete blood count and serum ferritin was done to support the exclusion criteria.

A thorough past medical history was taken from the patient’s and the attendant’s regarding oxygen saturation, requirement of hospitalization, oxygen therapy and ICU admission. Severity of COVID-19 disease was done according to the WHO criteria.

**COVID-19 disease severity classification**

- **Mild disease** - symptomatic patients meeting the case definition (fever, cough, fatigue, anorexia, myalgia, sore throat, nasal congestion, headache, diarrhoea, nausea and vomiting, anosmia and ageusia) without evidence of viral pneumonia or hypoxia with SpO2 ≥94%.

- **Moderate Disease** - with clinical signs of pneumonia (fever, cough, dyspnoea) with SpO2 90-93% on room air.

- **Severe Disease** - with clinical signs of pneumonia (fever, cough, dyspnoea) with SpO2 < 90% on room air.

- **Critical Disease** - severe pneumonia with oxygenation impairment requiring ICU admission.

**Statistical Analysis:**

Data were analyzed using SPSS 20. Means were calculated for descriptive analysis and Kruskal-Wallis Test was used for comparative analysis of ordinal variables. ‘p’ value less than 0.05 was considered significant.

**RESULTS**

The mean age of the study population was 31.0577±11.78 years with the maximum age 77 years and minimum age 16 years. There was a female preponderance with the numbers of female and male, 39 (75%) and 13 (25%) respectively.

The mean onset of hair loss after COVID-19 infection was 10.05 weeks. The onset of hair loss was significantly different in different COVID-19 severity groups with the shortest being in critical and the longest being in moderate groups. Among the patients with TE 16 (30.80%) presented with trichodynia.

Duration of COVID-19 symptoms was longer in higher severity groups (Figure 1).

There was statistically significant difference for the time of onset of hair loss when compared among the COVID-19 severity groups, p = 0.000 (Table I).

Association of trichodynia was significantly higher in higher severity groups of COVID-19 with p = 0.000 (Table II).
This increase in duration of illness might have led to increase in severity of COVID-19 increased duration of illness. As mentioned earlier our study showed significantly earlier in higher severity groups of COVID-19 with the p value of 0.00. As mentioned earlier our study showed increase in severity of COVID-19 increased duration of illness. This increase in duration of illness might have led to increase in stress among the more severe groups, which explains the early onset of hair loss in higher severity groups. The only exception in our study was that the onset was delayed in moderate group in comparison to the mild group, which may be due to excess of emotional stress as a consequence of anxiety in treating oneself with limited knowledge and psychological burden of preventing family members from infection during home isolation in the mild group.

Trichodynia was first observed and described as “the pain in the hair” by Sulzberger in 1960 as a distinctive symptom of TE and was first given its name as trichodynia by Alfredo Rebora. Its prevalence is around 20% and occurs in sites where hairs are actually shedding. In our study 30.08% patients presented with trichodynia. Our study also shows that the occurrence of trichodynia is greater with increase in severity of COVID-19 during the illness. When compared within the severity groups the percentage of occurrence of trichodynia was 0%, 25%, 75% and 80% in Mild, Moderate, Severe and Critical groups. Similarly a study done by Starace M et al showed that with increase in severity of COVID-19 disease TE is more associated with trichodynia.

**LIMITATIONS**

The limitation of the study was small sample size in individual severity groups of COVID-19. Trichoscopy was not done due to unavailability which could have supported our diagnosis.

**CONCLUSION**

Telogen Effluvium is common in post-COVID patients. Post-COVID TE is more common in females of early adulthood. The onset of TE is earlier and is more associated with Trichodynia with the increase in severity of COVID-19 during their illness. So in this current pandemic we should suggest that COVID-19 infection should be suspected and investigated in patients who presents with acute TE.

**REFERENCES**


